| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Lucidenic acid D targets cancer cell signaling pathways involved in proliferation and survival. It inhibits HepG2 cell proliferation and has demonstrated anti-cancer effects against hepatoma cells. The compound modulates key signaling pathways to inhibit cell proliferation and invasion. Its remarkable potential to stimulate apoptosis in cancer cells makes it an effective therapeutic candidate for combating cancer.
|
|---|---|
| ln Vitro |
In vitro, Lucidenic acid D inhibits HepG2 cell proliferation. It has demonstrated anti-cancer effects against hepatoma cells by inhibiting cell proliferation and invasion through modulation of key signaling pathways. The compound also exhibits anti-inflammatory and antioxidant properties. Its activity is typically assessed in cell-based assays measuring cell viability, apoptosis induction, and inflammatory marker expression.
|
| ln Vivo |
No specific in vivo activity data is publicly available for Lucidenic acid D. As a natural product-derived triterpenoid, its in vivo efficacy and pharmacokinetic properties have not been extensively characterized in the available literature. Further studies would be needed to establish its in vivo activity, particularly in animal models of cancer or inflammation.
|
| Enzyme Assay |
As a natural product, Lucidenic acid D is not typically evaluated in cell-free receptor binding assays. Its activity is assessed by measuring its effects on cancer cell signaling pathways in cell-based systems. The compound's antioxidant properties can be measured using standard cell-free assays such as DPPH radical scavenging or lipid peroxidation inhibition assays.
|
| Cell Assay |
In vitro cell-based experiments with Lucidenic acid D typically involve culturing cancer cell lines such as HepG2 (hepatoma cells). Cells are treated with various concentrations of the compound for 24-72 hours, and cell viability is assessed using MTT or SRB assays. Apoptosis is measured by flow cytometry using Annexin V/PI staining or by caspase-3/7 activity assays. The compound's effects on cell invasion can be assessed using Boyden chamber assays.
|
| Animal Protocol |
No specific in vivo animal protocols are publicly available for Lucidenic acid D. If in vivo studies were to be conducted, typical protocols might involve xenograft models in immunodeficient mice, where the compound would be administered, and tumor growth would be monitored.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data is publicly available for Lucidenic acid D. As a natural triterpenoid, its absorption, distribution, metabolism, and excretion (ADME) properties have not been characterized. The compound has a molecular weight of 514.61 and a molecular formula of C29H38O8.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is publicly available for Lucidenic acid D. As a natural product, its safety profile has not been well established. The compound is for research use only and is not intended for human therapeutic applications. No systemic toxicity studies have been reported.
|
| References | |
| Additional Infomation |
Lucidenic acid D2 is a triterpenoid compound. Lucidenic acid D has been reported in Ganoderma lucidum and Ganoderma sinensis, and relevant data are available for reference.
Lucidenic acid D has a molecular formula of C29H38O8 and a molecular weight of 514.61. It is a highly oxidized lanostane-type triterpenoid isolated from Ganoderma lucidum. The compound exhibits anti-cancer, anti-inflammatory, and antioxidant properties. It inhibits HepG2 cell proliferation and has demonstrated potential against hepatoma cells. It is available for research purposes only. |
| Molecular Formula |
C29H38O8
|
|---|---|
| Molecular Weight |
514.60722
|
| Exact Mass |
514.257
|
| CAS # |
98665-16-8
|
| PubChem CID |
23247891
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.884
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CCC(=O)O)[C@H]1CC(=O)[C@@]2([C@@]1([C@@H](C(=O)C3=C2C(=O)C[C@@H]4[C@@]3(CCC(=O)C4(C)C)C)OC(=O)C)C)C
|
| InChi Key |
LTJSBYAKDOGXLX-JTJCPSTFSA-N
|
| InChi Code |
InChI=1S/C29H38O8/c1-14(8-9-21(34)35)16-12-20(33)29(7)22-17(31)13-18-26(3,4)19(32)10-11-27(18,5)23(22)24(36)25(28(16,29)6)37-15(2)30/h14,16,18,25H,8-13H2,1-7H3,(H,34,35)/t14-,16-,18+,25-,27+,28+,29+/m1/s1
|
| Chemical Name |
(4R)-4-[(5R,10S,12S,13R,14R,17R)-12-acetyloxy-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9432 mL | 9.7161 mL | 19.4322 mL | |
| 5 mM | 0.3886 mL | 1.9432 mL | 3.8864 mL | |
| 10 mM | 0.1943 mL | 0.9716 mL | 1.9432 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
